financetom
Business
financetom
/
Business
/
Why Is Marvell Technology Stock Gaining Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Marvell Technology Stock Gaining Today?
Oct 17, 2024 2:47 PM

Marvell Technology, Inc. ( MRVL ) shares are trading higher on Monday. The company disclosed the development of the FBNIC, a custom 5nm network interface controller (NIC) ASIC created in partnership with Meta Platforms, Inc. ( META ) to address the company’s infrastructure needs.

Marvell ( MRVL ) will also contribute the FBNIC board design to the Open Compute Project (OCP) community.

The FBNIC integrates a custom network controller from Marvell ( MRVL ) with a co-designed board and Meta’s ASIC, firmware, and software.

This specialized design boosts capabilities, optimizes performance, enhances efficiency, and reduces the time needed to resolve network and server issues.

Raghib Hussain, President of Products and Technologies at Marvell ( MRVL ), said, “The future of large-scale, data center computing will increasingly revolve around optimizing semiconductors and other components for specific applications and cloud infrastructure architectures.”

“It’s been exciting to partner with Meta on developing their custom FBNIC on our industry-leading 5nm accelerated infrastructure silicon platform. We look forward to the OCP community leveraging the board design for future innovations.”

Marvell ( MRVL ) also announced that it will showcase next-generation silicon technologies, including PAM4 DSPs, PCIe retimers, Ethernet network switches, and Compute Express Link (CXL) devices at the 2024 OCP Global Summit, October 15-17, in San Jose, California.

Investors can gain exposure to the stock via Spear Alpha ETF ( SPRX ) and iShares U.S. Digital Infrastructure and Real Estate ETF

Price Action: MRVL shares are up 3.85% at $76.86 at the last check Monday.

Read Next:

Apple’s Low-Cost Vision Pro Could Hit The Shelves Next Year — Everything You Need To Know About iPhone Maker’s Plan To Challenge Meta

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Charter Communications Prices Tender Offer for Senior Secured Notes due 2025
Charter Communications Prices Tender Offer for Senior Secured Notes due 2025
May 23, 2024
02:43 PM EDT, 05/23/2024 (MT Newswires) -- Charter Communications ( CHTR ) said Thursday it has determined a total early offer consideration of $993.94 per $1,000 principal amount of notes in the tender offer for the company's outstanding 4.908% senior secured notes due 2025. The tender offer comprises the offer to purchase for cash up to $2.7 billion, the company...
BHP's Spinoff South32 Eyes Anglo American's Manganese Assets
BHP's Spinoff South32 Eyes Anglo American's Manganese Assets
May 23, 2024
South32 ( SHTLF ) Ltd (OTCPK: SHTLF), the diversified mining company spun out of BHP Group Ltd in 2015, has expressed interest in acquiring Anglo American's share of their jointly owned manganese assets. While BHP's acquisition efforts mainly focus on prized copper assets, Anglo American also announced restructuring amidst a strategic focus on copper and iron ore. “At the right...
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
May 23, 2024
On Wednesday, Royalty Pharma plc ( RPRX ) and Cytokinetics ( CYTK ) Incorporated entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline. The transaction includes funding for planned commercialization, development funding, royalty restructuring, revenue sharing, and the purchase of Cytokinetics ( CYTK ) equity.  Together, these provide Cytokinetics ( CYTK ) with $250 million on...
Hess-Chevron merger vote appears ripe for narrow approval
Hess-Chevron merger vote appears ripe for narrow approval
May 23, 2024
HOUSTON (Reuters) - Hess Corp ( HES ) CEO John Hess has until Tuesday to quell a rebellion by shareholders over his handling of what could turn out to be one of the largest mergers in oil industry history: a proposed $53 billion sale of the oil producer to Chevron Corp. ( CVX ) Hess, 70, has spent the past...
Copyright 2023-2026 - www.financetom.com All Rights Reserved